Drugs used in diabetes
Endocrine System | BNF Section 0601
Items (National)
73.9M
NHS Cost
£1,585.8M
Substances
58
Drugs in Drugs used in diabetes
| Drug | Items (National) | Cost | Practices |
|---|---|---|---|
| Metformin hydrochloride | 26.6M | £81.6M | 7,453 |
| Dapagliflozin | 8.9M | £322.1M | 7,140 |
| Gliclazide | 6.0M | £13.6M | 7,006 |
| Glucose blood testing reagents | 5.5M | £73.5M | 7,014 |
| Empagliflozin | 4.3M | £163.5M | 6,852 |
| Linagliptin | 2.7M | £78.4M | 6,651 |
| Insulin aspart | 2.6M | £111.5M | 6,931 |
| Sitagliptin | 2.6M | £5.7M | 6,707 |
| Insulin glargine | 2.0M | £88.8M | 6,927 |
| Semaglutide | 1.6M | £145.6M | 6,641 |
| Alogliptin | 1.4M | £38.1M | 5,574 |
| Tirzepatide | 1.3M | £137.2M | 6,596 |
| Canagliflozin | 847.8K | £33.7M | 5,905 |
| Insulin degludec | 723.7K | £43.0M | 6,585 |
| Dulaglutide | 710.6K | £58.7M | 6,201 |
| Biphasic isophane insulin | 697.3K | £23.8M | 6,250 |
| Isophane insulin | 693.3K | £18.8M | 6,567 |
| Biphasic insulin aspart | 661.0K | £32.2M | 6,510 |
| Pioglitazone hydrochloride | 513.1K | £995.1K | 5,802 |
| Insulin detemir | 499.4K | £28.1M | 6,377 |
| Insulin Lispro | 492.5K | £24.1M | 6,437 |
| Glimepiride | 452.0K | £482.2K | 4,899 |
| Ketone blood testing reagents | 444.2K | £9.0M | 6,564 |
| Glucose | 337.8K | £3.3M | 6,497 |
| Biphasic insulin lispro | 233.5K | £13.7M | 5,439 |
| Empagliflozin/metformin | 135.4K | £5.2M | 2,601 |
| Metformin hydrochloride/sitagliptin | 122.5K | £1.8M | 3,274 |
| Dapagliflozin/metformin | 105.6K | £4.1M | 2,405 |
| Glucagon | 92.4K | £2.2M | 6,076 |
| Saxagliptin | 91.0K | £2.8M | 2,721 |
| Insulin glulisine | 83.6K | £3.4M | 3,900 |
| Alogliptin/metformin | 57.7K | £1.6M | 1,384 |
| Urine testing reagents | 54.7K | £166.5K | 4,891 |
| Linagliptin/metformin | 52.3K | £1.7M | 1,553 |
| Repaglinide | 40.4K | £226.3K | 1,672 |
| Exenatide | 38.7K | £3.2M | 2,208 |
| Vildagliptin | 31.0K | £473.6K | 2,133 |
| Metformin hydrochloride/vildagliptin | 29.9K | £1.1M | 1,832 |
| Soluble insulin (Neutral insulin) | 24.2K | £1.0M | 2,512 |
| Acarbose | 19.7K | £463.4K | 1,690 |
| Ins degludec/liraglutide | 15.6K | £2.1M | 971 |
| Liraglutide | 14.7K | £1.8M | 2,751 |
| Ertugliflozin | 11.9K | £393.6K | 657 |
| Metformin hydrochloride/pioglitazone | 9,435 | £380.8K | 747 |
| Empagliflozin/linagliptin | 9,333 | £557.0K | 720 |
| Glipizide | 8,522 | £26.2K | 715 |
| Saxagliptin/dapagliflozin | 8,250 | £460.0K | 350 |
| Canagliflozin/metformin | 7,127 | £288.3K | 476 |
| Saxagliptin/metformin | 5,172 | £162.9K | 309 |
| Diazoxide | 2,344 | £345.3K | 284 |
| Tolbutamide | 2,018 | £365.3K | 159 |
| Insulin glargine/lixisenatide | 868 | £63.0K | 67 |
| Lixisenatide | 298 | £22.6K | 131 |
| Insulin human | 192 | £76.8K | 33 |
| Other screening and monitoring agent preparations | 145 | £1.9K | 13 |
| Glibenclamide | 107 | £30.8K | 22 |
| Glucose and ketone blood testing reagents | 37 | £987 | 20 |
| Nateglinide | 10 | £472 | 1 |